Ferrán Catalá-López1, Manuel Ridao, Gabriel Sanfélix-Gimeno, Salvador Peiró. 1. Fundación Instituto de Investigación en Servicios de Salud, Valencia, España; Centro Superior de Investigación en Salud Pública (CSISP), Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Valencia, España. Electronic address: ferran_catala@hotmail.com.
Abstract
OBJECTIVE: To describe the cost-effectiveness analyses of medications launched in Spain for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents. MATERIAL AND METHODS: Systematic review of the literature without meta-analysis. A search was made in, PubMed/MEDLINE, SCOPUS, databases of the Centre for Reviews and Dissemination, and the websites of technology assessment agencies from Canada, the United Kingdom and the Spanish Platform AUnETS. Only full economic evaluations were included, considering at least methylphenidate or atomoxetine as pharmacological treatment alternatives in children and/or adolescents with ADHD. RESULTS: Eleven studies published in 9 articles or reports were included. The most frequent characteristics were: cost-utility analysis (82%), health system perspective (82%), short-term horizon (91%), and private funding (50%). Methylphenidate was included in all studies, and atomoxetine in 4 studies. Methylphenidate and atomoxetine are cost-effective alternatives compared to placebo or no treatment, although incremental cost-effectiveness ratios are variable. The few direct treatment-comparisons between methylphenidate and atomoxetine provided contradictory and potentially biased results. CONCLUSIONS: The pharmacological treatment of ADHD in children and adolescents, with the reservations arising from the generalization of results to different settings, is probably cost-effective in the short term. The existing studies do not allow the relative efficiency of different treatments to be established, either in the long-term treatment or in patient subgroups with specific characteristics or comorbidities.
OBJECTIVE: To describe the cost-effectiveness analyses of medications launched in Spain for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents. MATERIAL AND METHODS: Systematic review of the literature without meta-analysis. A search was made in, PubMed/MEDLINE, SCOPUS, databases of the Centre for Reviews and Dissemination, and the websites of technology assessment agencies from Canada, the United Kingdom and the Spanish Platform AUnETS. Only full economic evaluations were included, considering at least methylphenidate or atomoxetine as pharmacological treatment alternatives in children and/or adolescents with ADHD. RESULTS: Eleven studies published in 9 articles or reports were included. The most frequent characteristics were: cost-utility analysis (82%), health system perspective (82%), short-term horizon (91%), and private funding (50%). Methylphenidate was included in all studies, and atomoxetine in 4 studies. Methylphenidate and atomoxetine are cost-effective alternatives compared to placebo or no treatment, although incremental cost-effectiveness ratios are variable. The few direct treatment-comparisons between methylphenidate and atomoxetine provided contradictory and potentially biased results. CONCLUSIONS: The pharmacological treatment of ADHD in children and adolescents, with the reservations arising from the generalization of results to different settings, is probably cost-effective in the short term. The existing studies do not allow the relative efficiency of different treatments to be established, either in the long-term treatment or in patient subgroups with specific characteristics or comorbidities.
Keywords:
Attention deficit-hyperactivity disorder; Children and adolescents; Cost-effectiveness; Coste-efectividad; Hiperactividad; Hyperactivity; Niños y adolescentes; Revisión sistemática; Systematic review; Trastorno por déficit de atención e hiperactividad
Authors: Javier Quintero; Josep A Ramos-Quiroga; Javier San Sebastián; Francisco Montañés; Alberto Fernández-Jaén; José Martínez-Raga; Marta García Giral; Montserrat Graell; María J Mardomingo; César Soutullo; Jesús Eiris; Montserrat Téllez; Montserrat Pamias; Javier Correas; Juncal Sabaté; Laura García-Orti; José A Alda Journal: BMC Psychiatry Date: 2018-02-08 Impact factor: 3.630